
Pia Krause Møller
@krause_moeller
Clinical Researcher, PhD, at the Department of Oncology (Radiotherapy section) @OncoCareOUH 👩⚕️#PatientReportedOutcome
ID: 998888642629263360
22-05-2018 11:29:45
87 Tweet
89 Followers
137 Following

Great 1st day: ePRO on #ESMO2023 with Ethan Basch presenting final results of the PRO-TECT trial. No benefit in OS for patients with metastatic disease but effect of ePRO on QoL and symptoms - important discussion of meaningful endpoints PRO ON Onkologisk Afdeling R, OUH Christina Ruhlmann
